Abstract：
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second most common cause of cancer death in the USA by 2030, yet progress continues to lag behind that of other cancers, with only 9% of patients surviving beyond 5 years. Long-term survivorship of PDAC and improving survival has, until recently, escaped our understanding. One recent frontier in the cancer field is the microbiome. The microbiome collectively refers to the extensive community of bacteria and fungi that colonise us. It is estimated that there is one to ten prokaryotic cells for each human somatic cell, yet, the significance of this community in health and disease has, until recently, been overlooked. This review examines the role of the microbiome in PDAC and how it may alter survival outcomes. We evaluate the possibility of employing microbiomic signatures as biomarkers of PDAC. Ultimately this review analyses whether the microbiome may be amenable to targeting and consequently altering the natural history of PDAC.
摘要：
到2030年，胰腺导管腺癌（PDAC）有望成为美国癌症死亡的第二大常见原因，但进展仍落后于其他癌症。只有9%的患者存活超过5年。PDAC的长期生存率和提高生存率，直到最近,逃脱了我们的理解。癌症领域的一个最新前沿是微生物组。微生物组统称为定殖我们的细菌和真菌的广泛群落。据估计，每个人体细胞有一到十个原核细胞，然而，这个社区在健康和疾病方面的重要性，直到最近,被忽视了。这篇综述探讨了微生物组在PDAC中的作用以及它如何改变生存结果。我们评估了使用微生物组学特征作为PDAC生物标志物的可能性。最终，这篇综述分析了微生物组是否适合靶向并因此改变PDAC的自然史。
